Home Newsfeeds Raymond James Maintains Outperform on Clorox, Raises Price Target to $165

Raymond James Maintains Outperform on Clorox, Raises Price Target to $165

Raymond James analyst Olivia Tong maintains Clorox (NYSE:CLX) with a Outperform and raises the price target from $160 to $165.

byBenzinga Newsdesk

February 3, 2023

1 minute read

Raymond James analyst Olivia Tong maintains Clorox (NYSE:CLX) with a Outperform and raises the price target from $160 to $165.

News

Why Safe & Green Holdings (SGBX) Shares Are Falling

By Henry Khederian

April 30, 12:28 PM

Safe & Green Holdings shares are trading lower by 19.2% during Tuesday's session. The company announced a planned reverse stock split at a ratio of 1-for-20.

SGBX

‘Rich Dad Poor Dad’ Author Robert Kiyosaki Flashes Fresh Warning About 401ks And IRAs Funds Going Up In Smoke: ‘The S&P Is Next’

By Shanthi Rexaline

December 11, 4:00 AM

Robert Kiyosaki, who has authored the best-selling personal finance book “Rich Dad, Poor Dad,” sounded a stark warning regarding the equity market on Sunday.

BTC

Analyst Ratings

Cracking The Code: Understanding Analyst Reviews For Cirrus Logic

By Benzinga Insights

May 16, 10:00 AM

In the preceding three months, 5 analysts have released ratings for Cirrus Logic (NASDAQ:CRUS), presenting a wide array…

CRUS

News

Reported Late Tuesday April 11, Eucrates Biomedical Acquisition Corp. Announces Liquidation; Co To Redeem All Outstanding Shares At A Per-Share Redemption Price Of ~$10

By Happy Mohamed

April 12, 12:59 AM

Eucrates Biomedical Acquisition Corp. (NASDAQ:EUCR) (the "Company") announced the following today: The Company anticipates that it will not be able to consummate an initial business combination within the

EUCR

Raymond James Maintains Outperform on Clorox, Raises Price Target to $165

Related Posts

Why Safe & Green Holdings (SGBX) Shares Are Falling

‘Rich Dad Poor Dad’ Author Robert Kiyosaki Flashes Fresh Warning About 401ks And IRAs Funds Going Up In Smoke: ‘The S&P Is Next’

Cracking The Code: Understanding Analyst Reviews For Cirrus Logic

Reported Late Tuesday April 11, Eucrates Biomedical Acquisition Corp. Announces Liquidation; Co To Redeem All Outstanding Shares At A Per-Share Redemption Price Of ~$10